European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Giovanni B. Frisoni; Cristina Festari; Federico Massa; Matteo Cotta Ramusino; Stefania Orini; Dag Aarsland; Federica Agosta; Claudio Babiloni; Barbara Borroni; Stefano F. Cappa; Kristian S. Frederiksen; Lutz Froelich; Valentina Garibotto; Alexander Haliassos; Frank Jessen; Anita Kamondi; Roy P. C. Kessels; Silvia D. Morbelli; John T. O'Brien; Markus Otto; Armand Perret-Liaudet; Francesca B. Pizzini; Mathieu Vandenbulcke; Ritva Vanninen; Frans Verhey; Meike W. Vernooij; Tarek Yousry; Mercè Boada Rovira; Bruno Dubois; Jean Georges; Oskar Hansson; Craig W. Ritchie; Philip Scheltens; Wiesje M. van der Flier; Flavio Nobili

doi:10.1016/S1474-4422(23)00447-7

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Giovanni B. Frisoni^*
, Cristina Festari
, Federico Massa
, Matteo Cotta Ramusino
, Stefania Orini
, Dag Aarsland
, Federica Agosta
, Claudio Babiloni
, Barbara Borroni
, Stefano F. Cappa
, Kristian S. Frederiksen
, Lutz Froelich
, Valentina Garibotto
, Alexander Haliassos
, Frank Jessen
, Anita Kamondi
, Roy P. C. Kessels
, Silvia D. Morbelli
, John T. O'Brien
, Markus Otto

Armand Perret-Liaudet, Francesca B. Pizzini, Mathieu Vandenbulcke, Ritva Vanninen, Frans Verhey, Meike W. Vernooij, Tarek Yousry, Mercè Boada Rovira, Bruno Dubois, Jean Georges, Oskar Hansson, Craig W. Ritchie, Philip Scheltens, Wiesje M. van der Flier, Flavio Nobili

^*Corresponding author for this work

University of Geneva
IRCCS Centro San Giovanni di Dio Fatebenefratelli - Brescia
University of Genoa
San Martino Hospital Genoa
IRCCS Fondazione Istituto Neurologico Casimiro Mondino - Pavia
University of Brescia
Stavanger University Hospital
King's College London
From the Neuroimaging Research Unit, Division of Neuroscience (P.P.), and Neurology Unite (P.P.), IRCCS San Raffaele Scientific Institute, Milan, Italy; and Department of Anatomy and Neurosciences (M.M.S.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands
Vita-Salute San Raffaele University
University of Rome La Sapienza
Hospital San Raffaele Cassino
Brescia Civil Hospital
Istituto Universitario di Studi Superiori di Pavia
University of Copenhagen
Heidelberg University
Universite de Geneve Faculte de Medecine
Center for Biomedical Imaging (CIBM)
ESEAP-Proficiency Testing Scheme for Clinical Laboratories
University of Bonn and German Center for Neurodegenerative Diseases (DZNE)
Med. Fac. of the Univ. of Cologne
Universität zu Köln
National Institute of Mental Health
Semmelweis University
Radboud University Nijmegen
Vincent Van Gogh Institute for Psychiatry
University of Cambridge
Martin Luther University Halle-Wittenberg
Unité d’Hygiène, Epidémiologie, Infectiovigilance et Prévention, Hospices Civils de Lyon, Lyon, France
Ospedale Policlinico
KU Leuven
University Hospital Gasthuisberg
University of Eastern Finland
University of Limburg
Erasmus University Rotterdam
University College London Hospitals NHS Foundation Trust
Institut Català de Neurociències Aplicades
Assistance publique – Hôpitaux de Paris
Sorbonne Université
Alzheimer Europe
Lund University
Skåne University Hospital
University of Edinburgh
Brain Health Scotland
Neuroscience Amsterdam

Research output: Contribution to journal › Review article › Academic › peer-review

50 Downloads (Pure)

Abstract

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

Original language	English
Pages (from-to)	302-312
Number of pages	11
Journal	The Lancet Neurology
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/S1474-4422(23)00447-7
Publication status	Published - 1 Mar 2024

Access to Document

10.1016/S1474-4422(23)00447-7

European-intersocietal-recommendations-for-the-biomarker-based-diagnosis-of-neurocognitive-disorders.pdfFinal published version, 368 KBLicence: CC BY

Cite this

Frisoni, G. B., Festari, C., Massa, F., Cotta Ramusino, M., Orini, S., Aarsland, D., Agosta, F., Babiloni, C., Borroni, B., Cappa, S. F., Frederiksen, K. S., Froelich, L., Garibotto, V., Haliassos, A., Jessen, F., Kamondi, A., Kessels, R. P. C., Morbelli, S. D., O'Brien, J. T., ... Nobili, F. (2024). European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Lancet Neurology, 23(3), 302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

@article{972d63bd1ea64c85addf82c3357d2ede,

title = "European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders",

abstract = "The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.",

author = "Frisoni, \{Giovanni B.\} and Cristina Festari and Federico Massa and \{Cotta Ramusino\}, Matteo and Stefania Orini and Dag Aarsland and Federica Agosta and Claudio Babiloni and Barbara Borroni and Cappa, \{Stefano F.\} and Frederiksen, \{Kristian S.\} and Lutz Froelich and Valentina Garibotto and Alexander Haliassos and Frank Jessen and Anita Kamondi and Kessels, \{Roy P. C.\} and Morbelli, \{Silvia D.\} and O'Brien, \{John T.\} and Markus Otto and Armand Perret-Liaudet and Pizzini, \{Francesca B.\} and Mathieu Vandenbulcke and Ritva Vanninen and Frans Verhey and Vernooij, \{Meike W.\} and Tarek Yousry and \{Boada Rovira\}, Merc{\`e} and Bruno Dubois and Jean Georges and Oskar Hansson and Ritchie, \{Craig W.\} and Philip Scheltens and \{van der Flier\}, \{Wiesje M.\} and Flavio Nobili",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = mar,

day = "1",

doi = "10.1016/S1474-4422(23)00447-7",

language = "English",

volume = "23",

pages = "302--312",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "3",

}

Frisoni, GB, Festari, C, Massa, F, Cotta Ramusino, M, Orini, S, Aarsland, D, Agosta, F, Babiloni, C, Borroni, B, Cappa, SF, Frederiksen, KS, Froelich, L, Garibotto, V, Haliassos, A, Jessen, F, Kamondi, A, Kessels, RPC, Morbelli, SD, O'Brien, JT, Otto, M, Perret-Liaudet, A, Pizzini, FB, Vandenbulcke, M, Vanninen, R, Verhey, F, Vernooij, MW, Yousry, T, Boada Rovira, M, Dubois, B, Georges, J, Hansson, O, Ritchie, CW, Scheltens, P , van der Flier, WM & Nobili, F 2024, 'European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders', The Lancet Neurology, vol. 23, no. 3, pp. 302-312. https://doi.org/10.1016/S1474-4422(23)00447-7

TY - JOUR

T1 - European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

AU - Frisoni, Giovanni B.

AU - Festari, Cristina

AU - Massa, Federico

AU - Cotta Ramusino, Matteo

AU - Orini, Stefania

AU - Aarsland, Dag

AU - Agosta, Federica

AU - Babiloni, Claudio

AU - Borroni, Barbara

AU - Cappa, Stefano F.

AU - Frederiksen, Kristian S.

AU - Froelich, Lutz

AU - Garibotto, Valentina

AU - Haliassos, Alexander

AU - Jessen, Frank

AU - Kamondi, Anita

AU - Kessels, Roy P. C.

AU - Morbelli, Silvia D.

AU - O'Brien, John T.

AU - Otto, Markus

AU - Perret-Liaudet, Armand

AU - Pizzini, Francesca B.

AU - Vandenbulcke, Mathieu

AU - Vanninen, Ritva

AU - Verhey, Frans

AU - Vernooij, Meike W.

AU - Yousry, Tarek

AU - Boada Rovira, Mercè

AU - Dubois, Bruno

AU - Georges, Jean

AU - Hansson, Oskar

AU - Ritchie, Craig W.

AU - Scheltens, Philip

AU - van der Flier, Wiesje M.

AU - Nobili, Flavio

PY - 2024/3/1

Y1 - 2024/3/1

N2 - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

AB - The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

UR - https://www.scopus.com/pages/publications/85185269773

U2 - 10.1016/S1474-4422(23)00447-7

DO - 10.1016/S1474-4422(23)00447-7

M3 - Review article

C2 - 38365381

SN - 1474-4422

VL - 23

SP - 302

EP - 312

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 3

ER -

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Abstract

Access to Document

Other files and links

Fingerprint

Cite this